248 related articles for article (PubMed ID: 28508871)
1. Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis.
Zhou M; Yang H; Learned RM; Tian H; Ling L
Nat Commun; 2017 May; 8():15433. PubMed ID: 28508871
[TBL] [Abstract][Full Text] [Related]
2. Regulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system.
Latasa MU; Salis F; Urtasun R; Garcia-Irigoyen O; Elizalde M; Uriarte I; Santamaria M; Feo F; Pascale RM; Prieto J; Berasain C; Avila MA
PLoS One; 2012; 7(12):e52711. PubMed ID: 23285165
[TBL] [Abstract][Full Text] [Related]
3. Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.
Zhou M; Wang X; Phung V; Lindhout DA; Mondal K; Hsu JY; Yang H; Humphrey M; Ding X; Arora T; Learned RM; DePaoli AM; Tian H; Ling L
Cancer Res; 2014 Jun; 74(12):3306-16. PubMed ID: 24728076
[TBL] [Abstract][Full Text] [Related]
4. FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4-GSK3β-Nrf2 Signaling.
Teng Y; Zhao H; Gao L; Zhang W; Shull AY; Shay C
Cancer Res; 2017 Nov; 77(22):6215-6225. PubMed ID: 28951455
[TBL] [Abstract][Full Text] [Related]
5. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y
Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355
[TBL] [Abstract][Full Text] [Related]
6. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
Mellor HR
Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
[TBL] [Abstract][Full Text] [Related]
7. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
Gao L; Shay C; Lv F; Wang X; Teng Y
Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785
[TBL] [Abstract][Full Text] [Related]
8. FGF19/SOCE/NFATc2 signaling circuit facilitates the self-renewal of liver cancer stem cells.
Wang J; Zhao H; Zheng L; Zhou Y; Wu L; Xu Y; Zhang X; Yan G; Sheng H; Xin R; Jiang L; Lei J; Zhang J; Chen Y; Peng J; Chen Q; Yang S; Yu K; Li D; Xie Q; Li Y
Theranostics; 2021; 11(10):5045-5060. PubMed ID: 33754043
[No Abstract] [Full Text] [Related]
9. Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukin-6 signaling in hepatocellular carcinoma.
Ploeger C; Waldburger N; Fraas A; Goeppert B; Pusch S; Breuhahn K; Wang XW; Schirmacher P; Roessler S
Hepatology; 2016 Sep; 64(3):828-42. PubMed ID: 27311882
[TBL] [Abstract][Full Text] [Related]
10. Novel Abs targeting the N-terminus of fibroblast growth factor 19 inhibit hepatocellular carcinoma growth without bile-acid-related side-effects.
Liu H; Zheng S; Hou X; Liu X; Du K; Lv X; Li Y; Yang F; Li W; Sui J
Cancer Sci; 2020 May; 111(5):1750-1760. PubMed ID: 32061104
[TBL] [Abstract][Full Text] [Related]
11. Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells.
Yang J; Cai X; Lu W; Hu C; Xu X; Yu Q; Cao P
Cancer Lett; 2013 Jan; 328(2):243-51. PubMed ID: 23032719
[TBL] [Abstract][Full Text] [Related]
12. FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma.
Huynh H; Prawira A; Le TBU; Vu TC; Hao HX; Huang A; Wang Y; Porta DG
Exp Mol Med; 2020 Nov; 52(11):1857-1868. PubMed ID: 33235319
[TBL] [Abstract][Full Text] [Related]
13. Monomeric/dimeric forms of Fgf15/FGF19 show differential activity in hepatocyte proliferation and metabolic function.
Williams CM; Harper Calderon J; E H; Jimenez Y; Barringer K; Carbonaro M; Molina-Portela MDP; Thurston G; Li Z; Daly C
FASEB J; 2021 Feb; 35(2):e21286. PubMed ID: 33484478
[TBL] [Abstract][Full Text] [Related]
14. FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis.
Ursic-Bedoya J; Desandré G; Chavey C; Marie P; Polizzi A; Rivière B; Guillou H; Assenat E; Hibner U; Gregoire D
EMBO Mol Med; 2024 Feb; 16(2):238-250. PubMed ID: 38228803
[TBL] [Abstract][Full Text] [Related]
15. Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis.
Gadaleta RM; Scialpi N; Peres C; Cariello M; Ko B; Luo J; Porru E; Roda A; Sabbà C; Moschetta A
Sci Rep; 2018 Nov; 8(1):17210. PubMed ID: 30464200
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus X protein promotes hepatocellular carcinoma transformation through interleukin-6 activation of microRNA-21 expression.
Li CH; Xu F; Chow S; Feng L; Yin D; Ng TB; Chen Y
Eur J Cancer; 2014 Oct; 50(15):2560-9. PubMed ID: 25087183
[TBL] [Abstract][Full Text] [Related]
17. Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma.
Lin ZZ; Hsu C; Jeng YM; Hu FC; Pan HW; Wu YM; Hsu HC; Hu MC; Cheng AL
Liver Int; 2019 Sep; 39(9):1682-1691. PubMed ID: 30698907
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of antitumor activity of Artemisia capillaris extract against hepatocellular carcinoma through the inhibition of IL-6/STAT3 signaling axis.
Jang E; Kim SY; Lee NR; Yi CM; Hong DR; Lee WS; Kim JH; Lee KT; Kim BJ; Lee JH; Inn KS
Oncol Rep; 2017 Jan; 37(1):526-532. PubMed ID: 28004112
[TBL] [Abstract][Full Text] [Related]
19. 17β-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling.
Lee S; Lee M; Kim JB; Jo A; Cho EJ; Yu SJ; Lee JH; Yoon JH; Kim YJ
Biochem Biophys Res Commun; 2016 May; 473(4):1247-1254. PubMed ID: 27091428
[TBL] [Abstract][Full Text] [Related]
20. The Role of Fibroblast Growth Factor 19 in Hepatocellular Carcinoma.
Chen Z; Jiang L; Liang L; Koral K; Zhang Q; Zhao L; Lu S; Tao J
Am J Pathol; 2021 Jul; 191(7):1180-1192. PubMed ID: 34000282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
